esmo group (esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation solutions, is proud to announce the launch of its latest product—the ...
There were no treatment-related deaths. Results are consistent with the data reported on the first 19 patients in Study 303 at ESMO in September. Published first on TheFly – the ultimate source for ...
A comprehensive analysis of the Phase II EBV CTL trial conducted at NCCS that identifies biomarkers will be presented at the ...
in patients with muscle-invasive bladder cancer (MIBC), according to findings from the phase 3 NIAGARA study presented at the ...
Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good day, everyone, and welcome to today’s BioAtla Third Quarter 2024 Earnings Call. [Operator Instructions] It is now my pleasure to turn ...
We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...
The largest ever clinical trial of T cell therapy (a type of cell-based immunotherapy) for solid tumours has been completed. Led by a Singapore clinician-investigator, the global, international, ...
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III ...
The largest ever clinical trial of T cell therapy for solid tumours has ended, heralding a new era for precision T cell ...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the third quarter ...
Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...
We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback